Efficacy of Lenalidomide in Myelodysplastic Syndromes
Top Cited Papers
Open Access
- 10 February 2005
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (6), 549-557
- https://doi.org/10.1056/nejmoa041668
Abstract
Ineffective erythropoiesis is the hallmark of myelodysplastic syndromes. Management of the anemia caused by ineffective erythropoiesis is difficult. In patients with myelodysplastic syndromes and symptomatic anemia, we evaluated the safety and hematologic activity of lenalidomide, a novel analogue of thalidomide.Keywords
This publication has 28 references indexed in Scilit:
- Myelodysplastic SyndromesHematology-American Society Hematology Education Program, 2004
- Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapyBlood, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromesLeukemia, 2002
- Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromesLeukemia, 1997
- Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor‐α concentrationBritish Journal of Haematology, 1997
- The use of r‐HuEpo in the treatment of anaemia related to myelodysplasia (MDS)British Journal of Haematology, 1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958